A61K 31/38
Having sulfur as a ring hetero atom
Official title: having sulfur as a ring hetero atom
A61K31/38 (Having sulfur as a ring hetero atom) appears on 2,976 US grants and 4,868 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,976
- Published applications
- 4,868
- Assignees
- 2,023
- Inventors
- 9,982
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 13 | 0 |
| 1977 | 8 | 0 |
| 1978 | 5 | 0 |
| 1979 | 8 | 0 |
| 1980 | 12 | 0 |
| 1981 | 8 | 0 |
| 1982 | 5 | 0 |
| 1983 | 3 | 0 |
| 1984 | 4 | 0 |
| 1985 | 6 | 0 |
| 1986 | 7 | 0 |
| 1987 | 5 | 0 |
| 1988 | 6 | 0 |
| 1989 | 14 | 0 |
| 1990 | 10 | 0 |
| 1991 | 18 | 0 |
| 1992 | 8 | 0 |
| 1993 | 15 | 0 |
| 1994 | 8 | 0 |
| 1995 | 32 | 0 |
| 1996 | 52 | 0 |
| 1997 | 60 | 0 |
| 1998 | 45 | 0 |
| 1999 | 46 | 0 |
| 2000 | 62 | 0 |
| 2001 | 77 | 13 |
| 2002 | 66 | 96 |
| 2003 | 54 | 162 |
| 2004 | 47 | 169 |
| 2005 | 46 | 168 |
| 2006 | 56 | 174 |
| 2007 | 30 | 165 |
| 2008 | 45 | 141 |
| 2009 | 47 | 153 |
| 2010 | 65 | 143 |
| 2011 | 59 | 181 |
| 2012 | 63 | 163 |
| 2013 | 118 | 208 |
| 2014 | 140 | 247 |
| 2015 | 140 | 271 |
| 2016 | 176 | 247 |
| 2017 | 167 | 256 |
| 2018 | 173 | 234 |
| 2019 | 144 | 209 |
| 2020 | 160 | 235 |
| 2021 | 134 | 231 |
| 2022 | 135 | 221 |
| 2023 | 89 | 197 |
| 2024 | 119 | 220 |
| 2025 | 98 | 202 |
| 2026 | 68 | 162 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Therapeutic uses of inhibitors of the RNA-binding protein HuR6 Oct 2026US 12,751,938 B2University of Kansas
- TEAD inhibitors29 Sep 2026US 12,747,207 B2Orion Corporation
- Methods for the treatment of conditions related to hydrogen sulfide22 Sep 2026US 12,740,968 B2Regents of the University of Minnesota
- Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto15 Sep 2026US 12,734,145 B2Children's Healthcare of Atlanta, Inc.
- Compounds for the treatment of bacterial infections and potentiation of antibiotics8 Sep 2026US 12,728,105 B2Georgia State University Research Foundation, Inc.
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
- Methods and pharmaceutical compositions comprising d1-like dopamine receptor agonist for the treatment of autosomal dominant polycystic kidney disease8 Oct 2026US 2026/0306504 A1Centre Hospitalier Universitaire De Rouen
- Compositions and methods for reducing blood ethanol concentration through alcohol dehydrogenase and acetaldehyde scavengers8 Oct 2026US 2026/0306589 A1Goa Therapeutics Corporation
- Uric acid transporter agonist compound, pharmaceutical composition, and preparation method therefor and use thereof8 Oct 2026US 2026/0308136 A1Hangzhou E & J Biopharmaceutical Technology Co., Ltd.
Most cited
By later US patents
- Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors192US 5,455,265 AAllergan, Inc. · 1995
- Method for inhibiting post-surgical adhesion formation by the topical administration of non-steroidal anti-inflammatory drug183US 4,937,254 AEthicon, Inc. · 1990
- Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents177US 6,403,649 B1Allergan Sales, Inc. · 2002
- Small organic molecule regulators of cell proliferation162US 6,613,798 B1Curis, Inc. · 2003
- Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects153US 9,700,528 B2Antecip Bioventures II LLC · 2017